Abstract
In 2009, the European Society of Hypertension (ESH) has developed a document updating the recommendations for the diagnosis and treatment of hypertension issued in 2007. The main elements of novelty refer to the assessment of organ damage, the blood pressure thresholds for treatment initiation as well as the blood pressure goals, the use of drug combination treatment and the therapeutic intervention in specific clinical conditions. This paper will review the novelties of the ESH update document and the implications of the “new guidelines” for current clinical practice.
Keywords: Guidelines, antihypertensive treatment, clinical trials, blood pressure, control, Hypertension, non-cardiovascular disease, European Society of Cardiology, hypertension treatment, microalbuminuria, renal damage, Modification of Diet in Renal Disease, left ventricular hypertrophy, antihypertensive drug treatment, cardiovascular risk, diuretics, β-blockers, calcium antagonists, ace-inhibitors, angiotensin II receptor, systolic and diastolic blood pressure, Telmisartan, Ramipril, European Lacidipine Study on Atheroscle-rosis, renin, aliskiren, POLYPILL, aspirin, coronary heart disease
Current Vascular Pharmacology
Title: What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document
Volume: 8 Issue: 6
Author(s): Giuseppe Mancia and Guido Grassi
Affiliation:
Keywords: Guidelines, antihypertensive treatment, clinical trials, blood pressure, control, Hypertension, non-cardiovascular disease, European Society of Cardiology, hypertension treatment, microalbuminuria, renal damage, Modification of Diet in Renal Disease, left ventricular hypertrophy, antihypertensive drug treatment, cardiovascular risk, diuretics, β-blockers, calcium antagonists, ace-inhibitors, angiotensin II receptor, systolic and diastolic blood pressure, Telmisartan, Ramipril, European Lacidipine Study on Atheroscle-rosis, renin, aliskiren, POLYPILL, aspirin, coronary heart disease
Abstract: In 2009, the European Society of Hypertension (ESH) has developed a document updating the recommendations for the diagnosis and treatment of hypertension issued in 2007. The main elements of novelty refer to the assessment of organ damage, the blood pressure thresholds for treatment initiation as well as the blood pressure goals, the use of drug combination treatment and the therapeutic intervention in specific clinical conditions. This paper will review the novelties of the ESH update document and the implications of the “new guidelines” for current clinical practice.
Export Options
About this article
Cite this article as:
Mancia Giuseppe and Grassi Guido, What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563942
DOI https://dx.doi.org/10.2174/157016110793563942 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Possible Target of Antioxidative Therapy for Diabetic Vascular Complications-Vascular NAD(P)H Oxidase
Current Medicinal Chemistry Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design The Influence of Sex Hormones on Pulmonary Vascular Reactivity: Possible Vasodilator Therapies for the Treatment of Pulmonary Hypertension
Current Vascular Pharmacology Role of Carbon Monoxide in Kidney Function: Is a little Carbon Monoxide Good for the Kidney?
Current Pharmaceutical Biotechnology Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design Metabolic and Cardiovascular Ageing Indices in Relation to Glycated Haemoglobin in Healthy and Diabetic Subjects
Current Aging Science L-4F Differentially Alters Plasma Levels of Oxidized Fatty Acids Resulting in more Anti-Inflammatory HDL in Mice
Drug Metabolism Letters Home Oxygen Therapy for the 21st Century
Current Respiratory Medicine Reviews Editorial [Hot Topic: Metabolic Syndrome in an Asian Chinese Population and Agents and Targets for Cardiovascular Protection (Guest Editors: M.L. Fung and T.M. Wong)]
Cardiovascular & Hematological Disorders-Drug Targets Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Protective Effects of Anesthetics on Vascular Function Related to K<sup>+</sup> Channels
Current Pharmaceutical Design Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab
Current Cancer Therapy Reviews Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Screening and Analysis of Hypolipidemic Components from Shuangdan Capsule Based on Pancreatic Lipase
Current Bioinformatics Coronary Risk Assessment and Management Options in Chronic Kidney Disease Patients Prior to Kidney Transplantation
Current Cardiology Reviews Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity
Mini-Reviews in Medicinal Chemistry Transient Receptor Potential Channels, the Kidney and Hypertension
Current Hypertension Reviews Targeting Leukocytes in Immune Glomerular Diseases
Current Medicinal Chemistry Withdrawal Notice: Atrial Fibrillation and Hypertension: “Quo Vadis”
Current Hypertension Reviews